Liquid biopsy is a check that examines deoxyribonucleic acid (DNA) and different molecules in a affected person’s blood to detect most cancers. Liquid biopsy performs a key position in early most cancers detection by offering a non-invasive methodology for detecting the presence of most cancers cells within the physique.
This check can detect circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in sufferers’ blood, indicating the presence of most cancers earlier than signs seem or earlier than a tumor may be seen on imaging checks.
This permits for earlier most cancers detection, resulting in earlier remedy and probably higher outcomes for sufferers. Moreover, liquid biopsy may also be used to observe the development of most cancers and assess the effectiveness of remedy, serving to make remedy selections and choice making to proceed or change remedy.
The healthcare trade has rapidly embraced liquid biopsy know-how for its accuracy, velocity, and comfort. It’s utilized in many hospitals and clinics worldwide and is turning into an integral a part of the healthcare trade. With its capability to detect most cancers in its early phases and with minimal discomfort to the affected person, it’s revolutionizing the best way healthcare professionals diagnose and deal with most cancers.
The workforce of professional analysts from the healthcare vertical at BIS Analysis has been finding out the position of liquid biopsy in early most cancers detection and its affect on the general healthcare trade, publishing a number of research across the identical.
BIS Analysis is internet hosting a webinar that may comprehensively view liquid biopsy.
Listed below are the small print:
Webinar Matter: Liquid Biopsy – An Rising Frontier in Early Multicancer Detection
Agenda: To know the next:
• Traits and key market developments• Frequent methodologies employed in liquid biopsy evaluation• Overview of rising scientific purposes and the testing panorama• Adoption state of affairs and key investments• Conclusion and future outlook
Causes to Attend the Webinar?
• To know the technological innovation in liquid biopsy• To establish elements limiting the liquid biopsy adoption in scientific software• To know how liquid biopsies might assist with remedy choice and monitoring of most cancers remedy outcomes• To discover market alternatives in numerous areas
Audio system:
Our eminent panelists for this webinar will likely be:
Azeet Narayan – Azeet Narayan is a Principal Scientist in Sema4. His primary pursuits lie in growing sequencing-based modern diagnostic assays to allow ultra-sensitive detection of nucleic acid biomarkers in scientific samples. His analysis curiosity contains various fields of bodily and bio-chemical sciences aimed toward reaching practical diagnostic options for difficult illnesses.
Nitish Kumar – Nitish Kumar is the principal advisor throughout the healthcare unit of BIS Analysis. He has a postgraduate diploma in pharmaceutical sciences and over eight years of expertise managing biopharma, life sciences, and biotechnology domains. Nitish has a profitable monitor report of consulting Fortune 500 purchasers within the bio-pharmaceuticals and life sciences area. He’s skilled in getting ready epidemiological-based knowledge fashions for biopharmaceutical merchandise.
Riya Gupta – Riya Gupta is a analysis analyst throughout the healthcare unit of BIS Analysis. Within the present position, Riya is accountable for finishing up complete qualitative and quantitative market info, which incorporates market dynamics like sizing, pattern evaluation, brief and long-term market forecasting, and aggressive panorama evaluation of the precision drugs trade.
Timing and Registration:
The webinar goes to happen on January 24, 2023, on the following time:
• 9:00 A.M. (EST/EDT)• 2:00 P.M. (GMP)• 7:30 PM (IST)
Go to our web site and register for the occasion at the moment. Get an edge over your rivals by studying the way forward for a sustainable house financial system.
